

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 01/24/17

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2)	Phase III	
		Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2)	Phase III	
		Secondary prevention of stroke in patients who have experienced Embolic Stroke of undetermined source (ESUS) (2)	Phase III	
		Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2)	Phase III	
	INVOKANA® (canagliflozin)	VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2)	Phase III	Phase III Phase III/IV
		Diabetic Nephropathy (2) Reduce the risk of death in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R) (2)	Phase III Phase III/IV	
Immunology	guselkumab	Moderate to Severe Plaque Psoriasis	Filed 11/16	Filed 11/16
	SIMPONI® ARIA™ (golimumab)	Ankylosing spondylitis Psoriatic arthritis Juvenile Idiopathic Arthritis (JIA)	Filed 12/16 Filed 12/16 Phase III	Filed 9/16 Approved 11/16 Phase III Phase III Approved 6/15
	sirukumab	Rheumatoid Arthritis (2)	Filed 9/16	
	STELARA® (ustekinumab)	Crohn's Disease Ulcerative Colitis Axial Spondylitis Pediatric Psoriasis	Approved 9/16 Phase III Phase III Filed 12/16	
Infectious Diseases and Vaccines	DARUNAVIR STR (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Phase III	Filed 9/16
	EDURANT® STR (rilpivirine and dolutegravir)	Single tablet regimen for HIV in treatment experienced patients (2)	Phase III	Phase III
	EDURANT® long acting maintenance (rilpivirine)	HIV Infection	Phase III	Phase III
Neuroscience	esketamine	treatment-resistant depression	Phase III	Phase III
Oncology	DARZALEX®	Relapsed/refractory multiple myeloma in combination with lenalidomide/dexamethasone (MMY3003) (2)	Approved 11/16	Filed 8/16
		Relapsed/refractory multiple myeloma in combination with bortezomib/dexamethasone (MMY3004) (2)	Approved 11/16	Filed 8/16
		Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenstrom's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Phase III	Phase III
		Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III
		Marginal Zone Lymphoma in patients who require systemic therapy and have received at least one prior anti-CD20- based therapy. (PCYC-1121) (2)	Approved 1/17	
		Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Phase III	
	apalutamide (ARN-509)	Prostate cancer pre-metastatic castration-resistant	Phase III	Phase III
		Metastatic hormone sensitive prostate cancer	Phase III	Phase III
		Localized prostate cancer	Phase III	Phase III
	apalutamide (ARN-509) / ZYTIGA® (abiraterone acetate)	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
	YONDELIS® (trabectedin)	Relapsed Ovarian Cancer (2)	Phase III	Phase III
	ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic		

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; PREZISTA STR and EDURANT STR (R/F/TF) developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with Viiv Healthcare; YONDELIS developed in collaboration with PharmaMar S.A.;

XARELTO co-developed with Bayer HealthCare; INVEGA SUSTENNA includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacycics, LLC, an AbbVie company; Sirukumab developed in collaboration with GlaxoSmithKline.

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of January 24, 2017

APPROVED 2015/2016	IN REGISTRATION	PLANNED FILINGS 2017-2019*	
Oncology	Immunology	Oncology	Neuroscience
YONDELIS® (US) (trabectedin) 2nd Line soft tissue sarcoma DARZALEX® (daratumumab) Double Refractory multiple myeloma	Sirukumab Rheumatoid arthritis Guselkumab Psoriasis	Apalutamide (ARN-509) Pre-metastatic prostate cancer	Esketamine Treatment resistant depression
		Imetelstat Relapsed/refractory myelofibrosis	JNJ-7922 (Orexin-2 antagonist) Primary insomnia
		Erdafitinib (FGFRI kinase inhibitor) Urothelial cancer Niraparib Metastatic castrate resistant prostate cancer	JNJ-1575 (AL-8176) RSV infection JNJ-3872 Influenza A JNJ-4178 (3DAA) (ACH-3102/AL-335/SMV) HCV

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Sirukumab developed in collaboration with GlaxoSmithKline; DARZALEX licensed from Genmab A/S; YONDELIS developed in collaboration with Pharma Mar S.A.; Orexin – 2 antagonist codeveloped with Minerva Neurosciences; Imetelstat licensed from Geron; JNJ-872 licensed from Vertex Pharmaceuticals, Inc.; ACH-3102 licensed from Achillion Pharmaceuticals, Inc.; Niraparib licensed from Tesaro